Shots: Under the expansion collaboration, new arm of assessment is added assessing BL-8040, Keytruda and chemo in 2L patient in COMBAT/KEYNOTE-202 study Results of Ph2a COMBAT study is expected in […]readmore
Shots: The extension provides a better understanding to clinicians and initial funding discoveries, molecular analyses, design and conduct of samples for new discoveries in cancer Agreement defines that Dana has […]readmore
Shots: U.S. FDA announces recalling of over 2,508 bottles of Metformin hydrochloride with an extended release tablets of 500 mg, packaged in a 500-count bottle Reason for recall is detection […]readmore
Shots: Imfinzi has been approved in unresectable PD-L1 expressing LA NSCLC patients treated with platinum-based CRT Approval is based post-hoc subgroup analyses by PD-L1 expression in addition to PFS & OS […]readmore
Shots: Keytruda sold $1.67Bn, 90% Y-o-Y, narrowly beating Opdivo’s $1.63Bn in Q2’18 Higher sales are observed as Keytruda in combination with Lilly’s Alimta and platinum chemo improves OS with 51% […]readmore
Shots: Hervycta (biosimilar Trastuzumab) indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer and metastatic gastric cancer) Marketed as 150mg and 440mg multiple dose vials As […]readmore
Shots: The drug failed to meet the primary endpoint of thyroid cancer lead to its failure as well as removal from phase 3, double blind involved in high risk DTC […]readmore
Shots: • The rejection of Ozanimod was based on unmet preclinical and clinical trials results, in patients with relapsing multiple sclerosis • Additionally, Celgene plans to resubmit […]readmore